{
    "ticker": "VSACU",
    "name": "VistaGen Therapeutics, Inc.",
    "description": "VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing new generation therapies for patients suffering from anxiety, depression, and other central nervous system (CNS) disorders. Founded in 1998 and headquartered in South San Francisco, California, VistaGen leverages its proprietary Human Clinical Trials in a Test Tube\u2122 platform, which is designed to reduce the risk of failure in drug development by using human stem cell technology to model human disease. The company\u2019s lead product candidate, AV-101, is being developed as a novel oral treatment for major depressive disorder and is currently undergoing clinical trials. VistaGen aims to address significant unmet medical needs in the mental health space, where traditional treatment options often come with limitations and side effects. In addition to AV-101, VistaGen is also advancing other candidates in its pipeline targeting various CNS disorders. The company is poised to contribute to the future of mental health treatment through innovative approaches and a commitment to enhancing the quality of life for patients.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "South San Francisco, California, USA",
    "founded": "1998",
    "website": "https://www.vistagen.com",
    "ceo": "Shawn Singh",
    "social_media": {
        "twitter": "https://twitter.com/VistaGen",
        "linkedin": "https://www.linkedin.com/company/vistagen-therapeutics/"
    },
    "investor_relations": "https://investors.vistagen.com",
    "key_executives": [
        {
            "name": "Shawn Singh",
            "position": "CEO"
        },
        {
            "name": "James E. R. A. C. M. E. B. A. C. A. C. H. P. H. D.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "AV-101",
                "PH94B"
            ]
        }
    ],
    "seo": {
        "meta_title": "VistaGen Therapeutics, Inc. | Innovative CNS Therapies",
        "meta_description": "Explore VistaGen Therapeutics, Inc., a leader in developing new therapies for anxiety and depression. Learn about our innovative approaches and pipeline.",
        "keywords": [
            "VistaGen",
            "Biotechnology",
            "Mental Health",
            "CNS Disorders",
            "AV-101",
            "Pharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What does VistaGen Therapeutics focus on?",
            "answer": "VistaGen Therapeutics focuses on developing new therapies for anxiety, depression, and other CNS disorders."
        },
        {
            "question": "What is AV-101?",
            "answer": "AV-101 is VistaGen's lead product candidate being developed for major depressive disorder."
        },
        {
            "question": "Where is VistaGen headquartered?",
            "answer": "VistaGen is headquartered in South San Francisco, California, USA."
        },
        {
            "question": "When was VistaGen founded?",
            "answer": "VistaGen was founded in 1998."
        }
    ],
    "competitors": [
        "LLY",
        "PFE",
        "ABT"
    ],
    "related_stocks": [
        "JNJ",
        "MRK",
        "BMY",
        "GILD"
    ]
}